Single-dose study of a corticotropin-releasing factor receptor-1 antagonist in women with 21-hydroxylase deficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 3, 2016, Pages 1174-1180

  Turcu, Adina F ^a   Spencer Segal, Joanna L ^a   Farber, Robert H ^c   Luo, Rosa ^c   Grigoriadis, Dimitri E ^c   Ramm, Carole A ^a   Madrigal, David ^a   Muth, Tim ^a   O'Brien, Christopher F ^c   Auchus, Richard J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GLUCOCORTICOID; HYDROXYPROGESTERONE; PLACEBO; TESTOSTERONE; VERUCERFONT; AZABICYCLO DERIVATIVE; CORTICOTROPIN RELEASING FACTOR RECEPTOR; OXADIAZOLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STEROID 21 MONOOXYGENASE DEFICIENCY; TERTIARY HEALTH CARE; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; YOUNG ADULT; ADRENAL HYPERPLASIA, CONGENITAL; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METABOLISM; TIME FACTOR;

17-ALPHA-HYDROXYPROGESTERONE; ADRENAL HYPERPLASIA, CONGENITAL; ADRENOCORTICOTROPIC HORMONE; ADULT; AZABICYCLO COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; OXADIAZOLES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TIME FACTORS; YOUNG ADULT;

EID: 84960858261     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3574     Document Type: Article

References (18)

1. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med. 2003;349:776-788.
2. Auchus RJ. The classic and nonclassic congenital adrenal hyperpla-sias. Endocr Pract. 2014:1-25.
3. Arlt W, Willis DS, Wild SH, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab. 2010;95:5110-5121.
4. Finkielstain GP, Kim MS, Sinaii N, et al. Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2012;97:4429-4438.
5. De Souza EB. Corticotropin-releasing factor receptors: physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinology. 1995;20:789-819.
6. Grigoriadis DE, Liu XJ, Vaughn J, et al. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2a receptors. Mol Pharmacol. 1996;50:679-686.
7. Maciejewski-Lenoir D, Heinrichs SC, Liu XJ, et al. Selective impairment of corticotropin-releasing factor1 (CRF1) receptor-mediated function using CRF coupled to saporin. Endocrinology. 2000;141: 498-504.
8. Chen C, Wilcoxen KM, Huang CQ, et al. Design of 2, 5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo [1, 5-a]py rimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-re-leasing factor receptor antagonists. J Med Chem. 2004;47:4787-4798.
9. Wood SK, McFadden KV, Grigoriadis D, Bhatnagar S, Valentino RJ. Depressive and cardiovascular disease comorbidity in a rat model of social stress: a putative role for corticotropin-releasing factor. Psychopharmacology (Berl). 2012;222:325-336.
10. Heinrichs SC, De Souza EB, Schulteis G, Lapsansky JL, Grigoriadis DE. Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology. 2002; 27:194-202.
11. Bryan SM, Honour JW, Hindmarsh PC. Management of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion. J Clin Endocrinol Metab. 2009;94:3477-3480.
12. Hindmarsh PC. The child with difficult to control Congenital Adrenal Hyperplasia: is there a place for continuous subcutaneous hy-drocortisone therapy. Clin Endocrinol (Oxf). 2014;81:15-18.
13. Mallappa A, Sinaii N, Kumar P, et al. Aphase2 study of chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endo-crinol Metab. 2015;100:1137-1145.
14. Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hed-ner T, Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol. 2009;161:119-130.
15. Holsboer F, Ising M. Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 2008;583:350-357.
16. Ising M, Zimmermann US, Kunzel HE, et al. High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuro-psychopharmacology. 2007;32:1941-1949.
17. Tellew JE, Lanier M, Moorjani M, et al. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2010;20:7259-7264.
18. Dunlop BW, Rothbaum BO, Binder EB, et al. Evaluation of a cor-ticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials. 2014;15:240.